CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alder Biopharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alder Biopharmaceuticals, Inc.
11804 North Creek Parkway South
Phone: (425) 205-2900p:425 205-2900 Bothell, WA  98011-8801  United States Fax: (425) 205-2901f:425 205-2901
This company was Merged or Acquired on 10/22/2019.
This company ceased filing statements with the SEC on 11/1/2019.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201912/31/2018YesYes-Yes-

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Robert W.Azelby 51 6/13/2018 6/13/2018
Chief Financial Officer CarlosCampoy 54 12/12/2018 12/12/2018
Chief Operating Officer Erin M.Lavelle 41 4/16/2018 4/16/2018
10 additional Officers and Directors records available in full report.

Business Names
Business Name
Alder BioPharmaceuticals Limited
Alder BioPharmaceuticals Pty. Ltd.
AlderBio Holdings LLC
ALDR

General Information
Number of Employees: 202 (As of 12/31/2018)
Outstanding Shares: 83,637,234 (As of 8/2/2019)
Shareholders: 20
Stock Exchange: NASD
Federal Tax Id: 900134860
Fax Number: (425) 205-2901
Email Address: info@alderbio.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023